Monopar Therapeutics Operating Income

Monopar Therapeutics (MNPR) currently reports a operating income of $-4.1B as of June 2026. That compares with $-4.8B in the prior-year period — up 14.5% year over year. Use the charts on this page to explore Monopar Therapeutics's operating income history and peer comparisons.

Monopar Therapeutics's operating income increased from $-4.8B to $-4.1B — a 14.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Monopar Therapeutics reported $-4.1B in operating income as of June 2026. That compares with $-4.8B in the prior-year period — up 14.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-4.1B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Monopar Therapeutics, and consider following MNPR for alerts when major investors trade the stock.

Monopar Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-4.1B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MNPR with unrelated industries.